MeSH tree: N04.761.559
Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit ...
Sep 15, 2026
0
5
Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion ...
Sep 13, 2026
0
7
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small ...
Sep 13, 2026
0
3
An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA ...
Sep 13, 2026
0
4
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic ...
Sep 12, 2026
0
10
The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared ...
Sep 12, 2026
0
5
Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated small cell lung ...
Sep 12, 2026
0
20
Mayo Clinic researchers have found that artificial intelligence (AI)-enabled spatial analysis can identify patterns in routine pathology slides that may help clinicians identify which patients with pancreatic cancer are at ...
Sep 11, 2026
0
5
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors responded to neoadjuvant immunochemotherapy (ICT) and who underwent less extensive surgery had high disease-free survival and organ ...
Sep 10, 2026
0
5
Results from an early-stage clinical trial, published in Nature Communications, showed encouraging outcomes among patients with newly diagnosed cancer whose tumors had spread to distant organs. Most strikingly, one patient ...
Aug 28, 2026
0
34
